Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II TrialPhilippe Armand, Leo I. Gordon, Jane N. Winter et al.|Journal of Clinical Oncology|2013Cited by 439